PT-141 Bremelanotide
PT-141 (Bremelanotide) is the only peptide that addresses libido and sexual desire at the neurological level — activating melanocortin receptors in the brain rather than manipulating hormones or blood flow. It works for both men and women, and is FDA approved for women with hypoactive sexual desire disorder.
FDA Approved
Vyleesi (2019) for women with HSDD
CNS-Mediated
Acts on brain, not hormones
1.75mg
Standard subcutaneous dose
45–60 min
Onset time post-injection
What Is PT-141?
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan-II, a research compound originally developed for skin tanning. During clinical trials, researchers noticed unexpected — and significant — effects on sexual arousal and desire, leading to PT-141's development as a dedicated sexual health peptide.
The compound acts as a melanocortin-4 receptor (MC4R) agonist in the central nervous system. The MC4R pathway, located in the hypothalamus, directly regulates sexual function, appetite, and energy expenditure. By activating these receptors, PT-141 stimulates neural circuits responsible for desire and arousal — without touching hormones like testosterone or estrogen.
This mechanism is fundamentally different from every other libido treatment on the market. Rather than correcting a deficiency or enhancing blood flow, it directly activates the brain's natural desire pathway.
MC4R Agonism
Binds melanocortin-4 receptors in the hypothalamus, activating the central neural circuits that initiate sexual desire and arousal responses.
Hormone-Independent
Does not alter testosterone, estrogen, or other sex hormones. Works even in the presence of normal hormone levels — addressing desire that exists independently of hormonal deficiency.
Derived from Melanotan-II
A cyclic peptide analog of alpha-MSH (melanocyte-stimulating hormone), structurally refined from Melanotan-II to eliminate tanning effects while preserving sexual function benefits.
Central vs Peripheral Action
Unlike PDE5 inhibitors (Viagra/Cialis) that act on peripheral blood vessels, PT-141 acts centrally in the brain — making it effective for psychogenic and desire-related dysfunction.
PT-141 vs Viagra / Cialis
PT-141 and PDE5 inhibitors address completely different aspects of sexual health. Understanding the distinction helps determine which is appropriate for your situation.
| Factor | PT-141 (Bremelanotide) | Viagra / Cialis (PDE5i) |
|---|---|---|
| Primary Mechanism | Central nervous system (MC4R agonism) | Vascular (PDE5 inhibition) |
| Works for | Both men and women | Primarily men |
| Addresses Desire | Yes — creates desire directly | No — requires existing arousal |
| Addresses Performance | Indirectly (via arousal) | Yes — improves erection quality |
| FDA Approval | Yes — Vyleesi for women (HSDD) | Yes — erectile dysfunction |
| Duration of Effect | 6–12 hours | 4–6h (Viagra) / 36h (Cialis) |
| Administration | Subcutaneous injection | Oral tablet |
| Best For | Low desire, HSDD, psychological dysfunction | Erectile dysfunction, vascular causes |
Male Protocol
Dosing for men
1.0 – 1.75 mg
Start at 1mg to assess tolerance; most men use 1.75mg
Subcutaneous injection
Abdomen or thigh — pinch the skin, inject at 45°
45–60 minutes before
Allow adequate time for CNS activation to occur
Max 1x per 72 hours
Minimum 3-day interval between doses
Men with erectile dysfunction may benefit from combining PT-141 with a low-dose PDE5 inhibitor — PT-141 addresses desire, while the PDE5i addresses vascular response. Consult a healthcare provider before combining compounds.
Female Protocol
Dosing for women (including FDA-approved Vyleesi)
1.25 mg (FDA-approved)
The Vyleesi-approved dose; some women use 1.75mg off-label
Subcutaneous injection
Abdomen or thigh — same technique as male protocol
45 minutes before
At least 45 minutes prior to anticipated sexual activity
HSDD — premenopausal women
Hypoactive sexual desire disorder; effective in perimenopause as well
PT-141 is clinically validated for premenopausal women with HSDD and has shown effectiveness in perimenopausal and postmenopausal contexts as well. Unlike testosterone therapy or flibanserin (Addyi), onset is rapid and on-demand.
PT-141 Side Effects
PT-141 has a well-studied side effect profile from both research trials and post-marketing data from its FDA approval as Vyleesi. Most effects are transient and manageable.
Nausea
Most Common (~40%)Peaks 30–60 minutes post-injection, resolves within 2–3 hours. Take on an empty stomach and consider 0.5mg ondansetron (anti-nausea) 30 min prior to significantly reduce incidence.
Flushing
CommonSkin warmth and redness, typically in face and neck. Transient — usually resolves within 1–2 hours. Not dangerous but can be uncomfortable. More common at higher doses.
Hyperpigmentation
Less CommonTransient darkening of skin at the injection site, or in areas exposed to sun. Usually temporary. Avoid excessive sun exposure during PT-141 use. Resolves after discontinuation.
Mild Headache
OccasionalTypically mild and self-limiting, occurring 1–3 hours post-dose. Staying well-hydrated before dosing reduces incidence. Does not require medication management in most cases.
Nausea Management Protocol
To significantly reduce PT-141 nausea: (1) Eat nothing for at least 2 hours before dosing — food in the stomach increases nausea frequency. (2) Take 0.5–1mg ondansetron (OTC anti-nausea) 30 minutes before injection. (3) Start with a lower test dose (0.5–1mg) on your first use to characterize your individual response before progressing to the standard 1.75mg dose.
Who Benefits Most from PT-141?
PT-141 is uniquely positioned for conditions where desire and motivation are the primary concern — not physical performance or hormonal imbalance.
Low Libido (Both Sexes)
For men and women experiencing reduced sexual desire without a clear hormonal cause, PT-141 directly activates the brain pathways responsible for desire. Often effective when standard interventions have failed.
HSDD in Women
Hypoactive sexual desire disorder affects an estimated 10% of premenopausal women. PT-141 is the only FDA-approved on-demand treatment for HSDD, with clinical trials showing significant improvements in desire and distress scores.
Antidepressant-Induced Dysfunction
SSRIs and SNRIs commonly cause sexual side effects by suppressing dopamine and other neurotransmitters. PT-141 operates through a separate pathway (melanocortin system), making it effective even in the presence of antidepressant use.
Stress-Related Desire Loss
Chronic stress suppresses libido through cortisol pathways that down-regulate hypothalamic sexual circuits. PT-141 bypasses these suppressive signals by directly activating MC4R, restoring desire independent of stress hormone levels.
Hormonal Transitions
Perimenopause, post-partum, and post-surgical hormonal changes often involve libido loss that is only partially addressed by hormone replacement. PT-141 provides a complementary, non-hormonal option that works alongside HRT.
Psychogenic Erectile Dysfunction
For men whose erectile dysfunction has a psychological or central nervous system component (performance anxiety, desire deficit) rather than purely vascular causes, PT-141 addresses the upstream driver that PDE5 inhibitors miss.
Explore All Peptide Protocols
PT-141 is one piece of the broader peptide landscape. Explore our comprehensive healing and optimization protocols to understand how peptides work synergistically for full-body health.
Explore Healing ProtocolsNew to Peptides?
Our beginner's guide covers everything — reconstitution, injection technique, sourcing, cycling, and which peptides to start with based on your goals. No prior experience required.
Read the Beginner GuidePT-141 FAQ
Does PT-141 work for both men and women?
Yes — PT-141 is one of the very few compounds with clinical trial evidence for both sexes. It was FDA approved specifically for premenopausal women with hypoactive sexual desire disorder (HSDD) under the name Vyleesi in 2019. Clinical trials also demonstrated meaningful improvements in male sexual desire and erectile function, particularly in cases where psychological or central factors were involved.
Why is PT-141 different from Viagra?
Viagra (sildenafil) and Cialis (tadalafil) work by inhibiting PDE5, an enzyme that regulates blood flow. They enhance erection quality by improving vascular response — but only if desire and arousal are already present. PT-141 works entirely differently: it activates melanocortin-4 receptors (MC4R) in the brain's hypothalamus, directly stimulating the neural circuits responsible for desire. It creates the motivation to engage, not just the physical capacity.
How do I reduce PT-141 nausea?
Nausea is the most common PT-141 side effect (~40% of users). To minimize it: take on an empty stomach at least 2 hours before dosing, consider 0.5mg ondansetron (Zofran, an anti-nausea medication) 30 minutes prior, and start with a lower test dose (0.5–1mg) to assess individual sensitivity before using the standard 1.75mg dose. Nausea typically peaks 30–60 minutes post-injection and resolves within 2–3 hours.
How often can I use PT-141?
No more than once per 72 hours (every 3 days). The FDA-approved Vyleesi label specifies this minimum interval, and research confirms that more frequent use increases both side effect burden and the risk of receptor desensitization, which reduces effectiveness over time. Treat PT-141 as an occasional therapeutic tool, not a daily supplement.
Ready to Learn More About Peptide Therapy?
From sexual health to healing, sleep, and body composition — explore our complete peptide education library and find the right protocol for your goals.
Related Reading